A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Orteronel (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 08 Jun 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Mar 2018.